Rat Prkaa2/Ampk/ Ampka2 ORF/cDNA clone-Adeno-associate virus(AAV) plasmid (NM_023991.1)
Pre-made Rat Prkaa2/Ampk/ Ampka2 Adeno-associated virus expression plasmid (ITR-vector) for Prkaa2 AAV packaging, Prkaa2 AAV production.The purified Rat Prkaa2/Ampk/ Ampka2 AAV particle serves as an invaluable asset for in-depth in vivo Prkaa2 studies, mechanism of action (MOA) research, and the evolution of Prkaa2-associated gene therapy strategies.
Our GM-AAV ITR vector is optimized with the G-NEXT™ multi-serotypes AAV vector system. Explore the G-NEXT™ system in detail.
Go
to PRKAA2/Prkaa2/Ampk products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Plasmid Grade | Plasmid quantity |
---|---|---|---|
pGMAAV000081 | Rat Prkaa2 Adeno-associate virus(AAV) plasmid | Research Grade | 10mg, 50mg, 100mg, 500mg, >1g |
GMP-like Grade | 10mg, 50mg, 100mg, 500mg, >1g | ||
High Quality (HQ) Grade | |||
Seed | 5ug |
Product Description
Catalog ID | pGMAAV000081 |
Gene Name | Prkaa2 |
Accession Number | NM_023991.1 |
Gene ID | 78975 |
Species | Rat |
Product Type | Adeno-associate virus(AAV) plasmid (overexpression) |
Insert Length | 1659 bp |
Gene Alias | Ampk, Ampka2 |
Fluorescent Reporter | |
Mammalian Cell Selection | Null |
Fusion Tag | 3xflag (C-Terminal) |
Promoter | CMV |
Resistance | Amplicin |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
---|---|---|
Target Antibody | GM-Tg-g-IP1444-Ab | Anti-PRKAA2 monoclonal antibody |
Target Antigen | GM-Tg-g-IP1444-Ag | PRKAA2 protein |
ORF Viral Vector | pGMAAV000081 | Rat Prkaa2 Adeno-associate virus(AAV) plasmid |
ORF Viral Vector | pGMLP001356 | Human PRKAA2 Lentivirus plasmid |
ORF Viral Vector | pGMLP001898 | Human PRKAA2 Lentivirus plasmid |
ORF Viral Vector | vGMAAV000081 | Rat Prkaa2 Adeno-associate virus(AAV) particle |
ORF Viral Vector | vGMLP001356 | Human PRKAA2 Lentivirus particle |
ORF Viral Vector | vGMLP001898 | Human PRKAA2 Lentivirus particle |
Target information
Target ID | GM-IP1444 |
Target Name | PRKAA2 |
Gene ID | 5563, 108079, 717703, 78975, 101096000, 489571, 538954, 100034159 |
Gene Symbol and Synonyms | 2310008I11Rik,A830082D05,AMPK,AMPK2,AMPKa2,AMPKalpha2,PRKAA,PRKAA2 |
Uniprot Accession | P54646 |
Uniprot Entry Name | AAPK2_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Not Available |
Disease | Not Available |
Gene Ensembl | ENSG00000162409 |
Target Classification | Kinase |
The protein encoded by this gene is a catalytic subunit of the AMP-activated protein kinase (AMPK). AMPK is a heterotrimer consisting of an alpha catalytic subunit, and non-catalytic beta and gamma subunits. AMPK is an important energy-sensing enzyme that monitors cellular energy status. In response to cellular metabolic stresses, AMPK is activated, and thus phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and beta-hydroxy beta-methylglutaryl-CoA reductase (HMGCR), key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. Studies of the mouse counterpart suggest that this catalytic subunit may control whole-body insulin sensitivity and is necessary for maintaining myocardial energy homeostasis during ischemia. [provided by RefSeq, Jul 2008]
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.